| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/26/2006 | WO2006112632A1 Urethral condoms and liquid femidoms |
| 10/26/2006 | WO2006112565A1 Therapeutic drugs for pollakiuria and urinary incontinence containing optical active propiophenon and its salts |
| 10/26/2006 | WO2006112556A1 Method for treating cancer using premedication |
| 10/26/2006 | WO2006112549A1 Fused heterocyclic compound |
| 10/26/2006 | WO2006112496A1 Method of producing proanthocyanidin-containing material |
| 10/26/2006 | WO2006112479A1 Nitrogen-containing heterocyclic compound |
| 10/26/2006 | WO2006112464A1 Piperazine-substituted benzothiophenes for treatment of mental disorders |
| 10/26/2006 | WO2006112456A1 Perkinson disease-related gene grk5 and use thereof |
| 10/26/2006 | WO2006112443A1 Novel method of using triacetin and auxiliary agent for ultrasonic diagnostic examination |
| 10/26/2006 | WO2006112442A1 Benzimidazole compound |
| 10/26/2006 | WO2006112441A1 Anti-hepatitis c virus agent containing bmp-7 |
| 10/26/2006 | WO2006112435A1 Phosphine transition metal complex, process for producing the same and anticancer drug containing the same |
| 10/26/2006 | WO2006112379A1 Drug for treating or diagnosing vascular lesion in the skin or the subcutaneous soft tissue caused by light irradiation |
| 10/26/2006 | WO2006112366A1 Lipopexia inhibitor and food or beverage |
| 10/26/2006 | WO2006112362A1 Process for production of polymer-type therapeutic agent for treatment of cancer |
| 10/26/2006 | WO2006112361A1 Polymeric pharmaceutical agent for treatment of cancer and process for production of the same |
| 10/26/2006 | WO2006112334A1 Sedative effect-providing agent and sedative fragrance composition containing the same |
| 10/26/2006 | WO2006112331A1 Novel condensed pyrrole derivative |
| 10/26/2006 | WO2006112330A1 Inhibitory agent for estrone-3-sulfate transporter activity |
| 10/26/2006 | WO2006112313A1 Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient |
| 10/26/2006 | WO2006112283A1 Anti-fatigue agent |
| 10/26/2006 | WO2006112276A1 Propofol-containing fat emulsion |
| 10/26/2006 | WO2006112239A1 hTERT GENE EXPRESSION REGULATORY GENE |
| 10/26/2006 | WO2006112222A1 Branched starch, process for production thereof, and use thereof |
| 10/26/2006 | WO2006112029A1 Ophthalmic composition |
| 10/26/2006 | WO2006112012A1 Nutrient composition |
| 10/26/2006 | WO2006111856A1 Pyrazole derivatives as progesterone receptor antagonists |
| 10/26/2006 | WO2006111853A2 Stable solid dosage forms of acid labile drug |
| 10/26/2006 | WO2006111844A1 Use of azithromycin for the production of a medicament for treatment of ocular infections |
| 10/26/2006 | WO2006111802A1 Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars |
| 10/26/2006 | WO2006111791A1 New anti-inflammatory compounds |
| 10/26/2006 | WO2006111783A1 Monosaccharide derivatives as anti-inflammatory and/or anti-cancer agents |
| 10/26/2006 | WO2006111759A1 Pyrrolobenzodiazepines |
| 10/26/2006 | WO2006111740A1 Benzo (b) cycloprop (d) pyran-2-(1h)-one derivatives |
| 10/26/2006 | WO2006111716A1 Heteroaryl derivatives having anti-mycobacterial activity |
| 10/26/2006 | WO2006111653A1 Use of agomelatine for obtaining medicaments used for treating bipolar disorders |
| 10/26/2006 | WO2006111648A1 H-pyrimido[4,5-b]indole derivatives, their preparation and therapeutic use |
| 10/26/2006 | WO2006111647A1 Association between ferroquine and an artemisinine derivative for treating malaria |
| 10/26/2006 | WO2006111624A2 Anti-inflammatory and/or analgesic composition for the intestine comprising branched maltodextrins |
| 10/26/2006 | WO2006111616A1 Peptide vaccine for influenza virus |
| 10/26/2006 | WO2006111596A1 Use of hdac6 protein tubulin deacetylase activity agonist compounds in the preparation of pharmaceutical compositions, said pharmaceutical compositions and applications of same in the treatment of viral infections |
| 10/26/2006 | WO2006111591A1 Method of preparing lycopene-enriched formulations that are free of organic solvents, formulations thus obtained, compositions comprising said formulations and use of same |
| 10/26/2006 | WO2006111560A2 2,3 substituted pyrazine sulfonamides as inhibitors of crth2 |
| 10/26/2006 | WO2006111549A1 Dihydrothienopyrimidines for the treatment of inflammatory diseases |
| 10/26/2006 | WO2006111517A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 10/26/2006 | WO2006111495A1 Roflumilast for the treatment of pulmonary hypertension |
| 10/26/2006 | WO2006111426A1 Composition of film-forming solution type, comprising vitamin d or a derivative thereof and a corticosteroid, and use thereof in dermatology |
| 10/26/2006 | WO2006111424A1 Methods for identifying modulators of cb1 and cb2 cannabinoid receptors and their use in wound healing |
| 10/26/2006 | WO2006111371A1 Pharmaceutically active diazepanes |
| 10/26/2006 | WO2006111355A1 Compositions for the prevention and the treatment of pain comprising phosphatidylethanolamine-binding protein (pebp) derived molecules |
| 10/26/2006 | WO2006111348A1 Use of heparin and heparin derivatives for modulating the neurite growth-controlling nogo receptor |
| 10/26/2006 | WO2006111346A1 Substituted cyclic urea derivatives and the use thereof as vanilloid receptor 1 modulators |
| 10/26/2006 | WO2006111321A1 Azole derivatives in the form of lipase and phospholipase inhibitors |
| 10/26/2006 | WO2006111296A2 Dosage forms and combined preparations of pyrimidine biosynthesis inhibitors for achieving additional effects upon the immune system |
| 10/26/2006 | WO2006111295A1 Method for treatment and prevention of respiratory insufficiency |
| 10/26/2006 | WO2006111261A1 Substituted 2-amin0alkylthi0-benzimidaz0les and use thereof for reducing blood sugar levels |
| 10/26/2006 | WO2006111198A1 Use of pde-5 inhibitors for endothelial repair of tissues impaired by trauma or disease |
| 10/26/2006 | WO2006111092A1 Preparation and application of heparin silver |
| 10/26/2006 | WO2006111085A1 A method, formulation and use thereor with improved oral absorption of drugs or nutrients |
| 10/26/2006 | WO2006111058A1 N4- (substituted oxycarbonyl)-2’,2’-difluoro-2’-deoxycytidines and uses thereof |
| 10/26/2006 | WO2006110931A1 Use of gallium (iii) complexes for treating tumours of the liver |
| 10/26/2006 | WO2006094237A3 Acridine and quinoline dervatives as sirtuin modulators |
| 10/26/2006 | WO2006093666A3 Isoqunoline compounds and methods of use thereof |
| 10/26/2006 | WO2006092727A3 Process for the production of calcium compositions in a continuous fluid bed |
| 10/26/2006 | WO2006091836A9 Formulations of ladostigil tartrate |
| 10/26/2006 | WO2006090268A3 Processes for the preparation of alfuzosin and salts thereof and novel crystalline forms of alfuzosin |
| 10/26/2006 | WO2006089861A3 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission |
| 10/26/2006 | WO2006086144A3 Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines |
| 10/26/2006 | WO2006085113A3 2-substituted 5-membered heteroaryl carboxylates as hm74a receptor agonists |
| 10/26/2006 | WO2006084694A3 Use of the mcm8 gene for the preparation of a pharmaceutical composition |
| 10/26/2006 | WO2006083271A3 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| 10/26/2006 | WO2006079568A3 Use of 3-sulfanylpropanamide derivatives for stimulating hair and eyelash growth and/or for stopping the loss and/or limiting the depigmentation thereof |
| 10/26/2006 | WO2006075993A3 Nucleoside derivatives for treating hepatitis c virus infection |
| 10/26/2006 | WO2006075255A3 Anti-inflamatory macrolide conjugates |
| 10/26/2006 | WO2006075012A3 Pyrrolodihydroisoquinolines as antiproliferative agents |
| 10/26/2006 | WO2006075004A3 3, 8 - substituted 8-aza-bicyclo[3.2.1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 10/26/2006 | WO2006074057A3 Pyrimidine derivatives as kinase modulators and method of use |
| 10/26/2006 | WO2006066923A3 Indole derivatives with antitumor activity |
| 10/26/2006 | WO2006065448A3 Topoisomerase inhibitors and prodrugs |
| 10/26/2006 | WO2006063707A3 Novel pharmaceutical composition containing at least one dolastatin 10 derivative |
| 10/26/2006 | WO2006063058A3 Small molecule inhibitors of bacterial dam dna methyl transferases |
| 10/26/2006 | WO2006060598A3 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN AND INTERLEUKIN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 10/26/2006 | WO2006060542A3 Formulations of substituted benzoxazoles |
| 10/26/2006 | WO2006060384A3 Formulations of substituted benzoxazoles |
| 10/26/2006 | WO2006058869A3 Substituted pteridines for treating inflammatory diseases |
| 10/26/2006 | WO2006058867A3 Substituted pteridines for the treatment of inflammatory diseases |
| 10/26/2006 | WO2006057950A3 4-phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 10/26/2006 | WO2006057578A3 Method for preventing and correcting a chronic desynchronosis of human organism organs and systems and a chrono-biological correction agent |
| 10/26/2006 | WO2006053150B1 Pharmaceutical compositions for topical application on the treatment of age-related macular degeneration and ocular hypertension |
| 10/26/2006 | WO2006052936A3 Compounds and compositions as protein kinase inhibitors |
| 10/26/2006 | WO2006042056A3 Methods and compositions for enzyme-specific activation of carbohydrate-conjugated prodrugs |
| 10/26/2006 | WO2006028962A3 1-alkoxy 1h-imidazo ring systems and methods |
| 10/26/2006 | WO2006021399A3 Azabicyclononene derivatives as renin inhibitors |
| 10/26/2006 | WO2006020244A3 Compositions and methods related to heart failure |
| 10/26/2006 | WO2006019430B1 Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
| 10/26/2006 | WO2006015357A3 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| 10/26/2006 | WO2006010641A3 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
| 10/26/2006 | WO2006001035A3 Synergistic liposomal tamoxifen composition for topical application and method of preparing thereof. |
| 10/26/2006 | WO2005119261A3 Glut5 transporters expressed in cancer cells |
| 10/26/2006 | WO2005113534A3 Cxcr1 and cxcr2 chemokine antagonists |